drugset
drugset / Trial / NCT04950075

Study of INBRX-109 in Conventional Chondrosarcoma

NCT04950075 ↗

Phase 2 Active not recruiting 206 enrolled Inhibrx Biosciences, Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.

Timeline

Start
2021-09-23
Primary completion
2025-09-30
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject OZEKIBART Monoclonal antibody — Intravenous

Indications

chondrosarcoma